Latest PD-1 Stories
ASCO Presentations Shed Light on Biomarkers for Rare and Resistant GIST Subtypes and for Triple Wild-type Melanoma IRVING, Texas, May 28, 2015 /PRNewswire/ -- Caris Life Sciences,
Data Demonstrates Extension of Survival of Metastatic Melanoma Patients Treated with Proleukin Followed by Immune Checkpoint Blockade of the Programmed Death (PD-1/PD-L1) Pathway CHICAGO,
SAN DIEGO, May 20, 2015 /PRNewswire/ -- OncoSec Medical Inc.
Preliminary Results Suggest ImmunoPulse(TM) IL-12 May Generate Increased TILs and CD8+ T-Cell Infiltration in Merkel Cell Carcinoma and Melanoma Patients SAN DIEGO, May 7, 2015 /PRNewswire/
The Mesothelioma Applied Research Foundation is optimistic about the results of the Phase 1b trial of pembrolizumab for PD-L1-positive advanced solid tumors, which were announced at the most recent
Data from KEYNOTE-006 Study Presented at AACR Annual Meeting and Published in the New England Journal of Medicine KIRKLAND, QC, April 19, 2015 /CNW Telbec/ - Merck (NYSE: MRK),
KIRKLAND, QC, April 19, 2015 /CNW Telbec/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating pembrolizumab,
NEW YORK and ANN ARBOR, Mich., April 8, 2015 /PRNewswire/ -- Lycera Corp., a biopharmaceutical company developing breakthrough
Research Provides Potential Implications for Immunotherapy in Treatment of Gynecologic Cancers IRVING, Texas, March 29, 2015 /PRNewswire/ -- Caris Life Sciences® today announced the
CALGARY, March 26, 2015 /PRNewswire/ - Oncolytics Biotech(®) Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.